SCHEMBL5137577

SCHEMBL5137577

CCCCN(Cc1ccccc1F)Cc1c(-c2ccccc2)nc(-c2ccccc2)n1CCCC

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.43
TSHR P16473 3/20 0.42
TP53 P04637 1/20 0.39
GAA P10253 1/20 0.39
ALDH1A1 P00352 5/20 0.39
KDM4E B2RXH2 4/20 0.39
HPGD P15428 4/20 0.39
HSD17B10 Q99714 4/20 0.39
CYP3A4 P08684 3/20 0.39
HDAC1 Q13547 1/20 0.38
GNRHR P30968 1/20 0.37
NR1H3 Q13133 1/20 0.36
DRD2 P14416 1/20 0.36
DRD3 P35462 1/20 0.36
CRHR1 P34998 1/20 0.35
PDE4B Q07343 1/20 0.35
ATP4A P20648 1/20 0.35
ATP4B P51164 1/20 0.35
CNR2 P34972 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5135121 0.97 C5AR1 (0.41) C5AR1TSHRTP53GAAALDH1A1
SCHEMBL5135185 0.96 C5AR1 (0.43) C5AR1TSHRTP53GAAALDH1A1
SCHEMBL5137572 0.96 C5AR1 (0.39) C5AR1TSHRTP53GAAALDH1A1
SCHEMBL5169689 0.94 C5AR1 (0.40) C5AR1TSHRTP53GAAALDH1A1
SCHEMBL652221 0.93 C5AR1 (0.42) C5AR1TSHRTP53GAAALDH1A1
SCHEMBL5136473 0.93 C5AR1 (0.44) C5AR1TSHRTP53GAAALDH1A1
SCHEMBL5165790 0.93 GNRHR (0.46) C5AR1TSHRGAAALDH1A1KDM4E
SCHEMBL5134844 0.91 C5AR1 (0.44) C5AR1TSHRALDH1A1KDM4EHPGD
SCHEMBL5136299 0.91 C5AR1 (0.45) C5AR1TSHRTP53GAAALDH1A1
SCHEMBL5135670 0.90 C5AR1 (0.43) C5AR1TSHRALDH1A1KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed